Piper Sandler has resumed coverage of Supernus Pharmaceuticals with an 'Overweight' rating and a $47 price target. This positive analyst coverage highlights the company's enhanced M&A capabilities post-Indivior merger and strong revenue growth projections from key products, suggesting potential upside for the stock.
Piper Sandler has reinstated coverage on Supernus Pharmaceuticals with an 'Overweight' rating and a $47 price target. This positive analyst action is driven by the strategic merger with Indivior, which is expected to significantly boost Supernus's business development and M&A capabilities. The firm projects strong revenue growth from key products like Sublocade, Qelbree, Zurzuvae, and Onapgo, which are anticipated to account for 80% of revenue by 2027, supported by long exclusivity periods. This outlook suggests a positive short-term sentiment for SUPN due to the analyst endorsement and a long-term opportunity for growth and larger strategic acquisitions, potentially attracting investors looking for pharmaceutical companies with strong product pipelines and M&A potential.